Table 5 Patient survival overall and by Okuda stage and CLIP score
From: Thymostimulin in advanced hepatocellular carcinoma: A phase II trial
Thymostimulin (present data) | Okuda et al. 1985 [16] | CLIP 2000 [17] | ||||
|---|---|---|---|---|---|---|
1-year survival | 2-year survival | 1-year survival | 2-year survival | 1-year survival | 2-year survival | |
Overall | 50 % | 23 % | 26 % | 15 % | 48 % | 28 % |
Okuda stage | ||||||
I | 69 % | 38 % | 49 % | 32 % | 68 % | 48 % |
II | 40 % | 11 % | 18 % | 9 % | 36 % | 13 % |
III | 0 %* | 0 %* | 3 % | 3 % | 21 % | 10 % |
CLIP score | ||||||
0 | 100 %* | 100 %* | 84 % | 65 % | ||
1 | 70 % | 40 % | 66 % | 45 % | ||
2 | 60 % | 20 % | 45 % | 17 % | ||
3 | 30 % | 10 % | 36 % | 12 % | ||
4–6 | 14 %* | 0 %* | 9 % | 0 % | ||